Inebilizumab: First Approval.
Drugs
; 80(12): 1259-1264, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32729016
ABSTRACT
Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19 monoclonal antibody being developed by Viela Bio for the treatment of a range of autoimmune diseases associated with CD19-expressing B cells. Inebilizumab targets and depletes CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity. In June 2020, inebilizumab received its first global approval in the USA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are seropositive for immunoglobulin G autoantibodies against aquaporin-4 (AQP4-IgG). The drug is also undergoing clinical evaluation for kidney transplant desensitization, myasthenia gravis, and IgG4-related disease. This article summarizes the milestones in the development of inebilizumab leading to this first approval for the treatment of AQP4-IgG seropositive NMOSD.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neuromielitis Óptica
/
Aprobación de Drogas
/
Anticuerpos Monoclonales Humanizados
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Drugs
Año:
2020
Tipo del documento:
Article
País de afiliación:
Nueva Zelanda